EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Neurological Impact of Caplacizumab in Refractory iTTP Survivors: A Comparative Study of Blood-Brain-Barrier Integrity and Cognitive Outcomes

Fahad Hannan iD, Jonathan D Thiessen iD, Christopher J Patriquin iD, Katerina Pavenski iD, Leandro Tristao, Ting-Yim Lee iD, Daniel Mendes, Jean Théberge iD, Jennifer L Mandzia iD, Melissa Al-Jaishi, Kerri L Gallo iD, Shih-Han Susan Huang iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2026

DOI: 10.1161/atvbaha.126.324382 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Fahad Hannan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biophysics (F.H., J.D.T., J.T., S.-H.S.H.), Schulich School of Medicine and Dentistry, Western University, London, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Blood-Brain Barrier, Cognition, Cognition Disorders. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) causes systemic microvascular thrombosis, often leading to long-term neurological complications and cognitive decline despite achieving hematologic remission. Persistent blood-brain barrier (BBB) dysfunction is a suspected driver of these chronic sequelae. This study investigated whether adding caplacizumab to standard of care (SOC) improves long-term BBB integrity and cognitive outcomes in refractory iTTP survivors compared with SOC alone. METHODS: We analyzed 16 patients with iTTP categorized into SOC-only (n=7) or SOC plus caplacizumab (n=9) cohorts. Patients underwent computed tomography perfusion imaging to measure BBB permeability (PS product), blood flow, and blood volume at baseline (30 days postremission) and 12-month follow-up. Cognitive function was assessed using Creyos (URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03187652). RESULTS: At baseline, the caplacizumab group, composed largely of refractory cases, exhibited nominally higher BBB permeability than the SOC-only group (0.48±0.11 mL/min per 100 grams versus 0.38±0.14 mL/min per 100 grams, P =0.048, Cohen d=0.73 [95% CI, −0.277 to −0.001]), an exploratory finding. The primary outcome, within-group BBB-PS reduction in the SOC plus caplacizumab group at 12 months, was significant (0.37±0.09 mL/min per 100 grams, P =0.027, Cohen d=0.90 [95% CI, 0.016–0.203]), while the SOC-only group showed minimal change. Despite variations in rituximab administration due to regional funding restrictions, higher BBB permeability was moderately to strongly correlated with lower scores across all cognitive domains and lower ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats 13) activity ( q

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBlood-Brain BarrierCognitionCognition DisordersFibrinolytic AgentsPurpura, Thrombocytopenic, IdiopathicAdultAgedFemaleHumansMaleMiddle AgedCapillary PermeabilityPerfusion ImagingTime FactorsTreatment OutcomeSingle-Domain Antibodies

Stichwörter der Autor:innen

blood-brain barriercaplacizumabdisintegrinperfusion imagingthrombosis

Substanzen

Antibodies, Monoclonal, HumanizedcaplacizumabFibrinolytic AgentsSingle-Domain Antibodies

Autor:innen und Institutionen

  • Department of Medical Biophysics (F.H., J.D.T., J.T., S.-H.S.H.), Schulich School of Medicine and Dentistry, Western University, London, Canada.
  • Division of Medical Physics, CancerCare Manitoba, Winnipeg, Canada (J.D.T.).
  • Department of Radiology, University of Manitoba, Winnipeg, Canada (J.D.T.).
  • Lawson Imaging, Lawson Health Research Institute, London, Canada (J.D.T., T.-Y.L., J.T., S.-H.S.H.).
  • Division of Medical Oncology & Hematology, University Health Network, Toronto, Canada (C.J.P.).
  • Department of Medicine (Hematology) (C.J.P.), University of Toronto, Canada.

ORCID-Profile: Fahad Hannan, Jonathan D Thiessen, Christopher J Patriquin, Katerina Pavenski, Ting-Yim Lee, Jean Théberge, Jennifer L Mandzia, Kerri L Gallo, Shih-Han Susan Huang

Zitieren

APA

Hannan, F., Thiessen, J. D., Patriquin, C. J., Pavenski, K., Tristao, L., Lee, T. Y., Mendes, D., Théberge, J., Mandzia, J. L., Al-Jaishi, M., Gallo, K. L., & Huang, S. S. (2026). Neurological Impact of Caplacizumab in Refractory iTTP Survivors: A Comparative Study of Blood-Brain-Barrier Integrity and Cognitive Outcomes. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.126.324382

Vancouver

Hannan F, Thiessen JD, Patriquin CJ, Pavenski K, Tristao L, Lee TY, et al. Neurological Impact of Caplacizumab in Refractory iTTP Survivors: A Comparative Study of Blood-Brain-Barrier Integrity and Cognitive Outcomes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.126.324382

BibTeX
@article{Hannan2026,
  author = {Hannan, Fahad and Thiessen, Jonathan D and Patriquin, Christopher J and Pavenski, Katerina and Tristao, Leandro and Lee, Ting-Yim and Mendes, Daniel and Théberge, Jean and Mandzia, Jennifer L and Al-Jaishi, Melissa and Gallo, Kerri L and Huang, Shih-Han Susan},
  title = {Neurological Impact of Caplacizumab in Refractory iTTP Survivors: A Comparative Study of Blood-Brain-Barrier Integrity and Cognitive Outcomes},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2026},
  doi = {10.1161/atvbaha.126.324382}
}
Kostenlos starten →